✦ LIBER ✦

Using clinical trial data to tailor adjuvant treatments for individual patients

✍ Scribed by Meredith M. Regan; Richard D. Gelber

Book ID: 113506921
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 178 KB
Volume: 16
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2007.07.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

S26 Using clinical trial data to tailor

S26 Using clinical trial data to tailor adjuvant treatments for individual patients

✍ R.D. Gelber; A. Goldhirsch 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Tailoring adjuvant treatments for the in

Tailoring adjuvant treatments for the individual breast cancer patient

✍ R.D Gelber; M Bonetti; M Castiglione-Gertsch; A.S Coates; A Goldhirsch 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Causes for the undertreatment of elderly

Causes for the undertreatment of elderly breast cancer patients: tailoring treatments to individual patients

✍ Vic Velanovich; Molly Gabel; Eleanor M Walker; Thomas J Doyle; Robert M O’Bryan; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 180 KB

Use of luteinising-hormone-releasing hor

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 341 KB

Combining individual patient data and ag

Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: Individual patient data may be beneficial if only for a subset of trials

✍ Sarah Donegan; Paula Williamson; Umberto D'Alessandro; Paul Garner; Catrin Tudur 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 336 KB

POWER CONSIDERATIONS FOR CLINICAL TRIALS

POWER CONSIDERATIONS FOR CLINICAL TRIALS USING MULTIVARIATE TIME-TO-EVENT DATA

✍ MICHAEL D. HUGHES 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 2 views

Many clinical trials involve the collection of data on the times to occurrence of different types of events, such as different fungal infections in AIDS research, or of recurrences of the same type, such as successive fits in epilepsy research. The multivariate proportional hazards model allows for